Cilamox is indicated for the treatment of infections due to susceptible strains of the sensitive organisms: Gram-negative: H. influenzae, E. coli, Pr. mirabilis, and N. gonorrhoeae.
Gram-positive: Streptococcus species, S. pneumoniae, non-penicillinase producing Staphylococci and Bacillus anthracis.
Note 1: Cilamox may be useful in instituting therapy prior to bacteriology; however, bacteriological studies to determine the causative organisms and their sensitivity to Cilamox should be performed.
Note 2: Penicillins are now generally regarded only as adjunctive to some other established first-line antibiotic therapy in the treatment and post-exposure prophylaxis of anthrax, because of concerns of constitutive and inducible beta-lactamase in Bacillus anthracis. If use of amoxicillin is contemplated, appropriate bacteriological studies must be performed by a reliable and established test method. Amoxicillin may then be suitable if the specific B. anthracis strain has been shown definitively to be sensitive to penicillin/amoxicillin.